Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PD-L1 gene modified bone marrow mesenchymal stem cells in graft rejection

A PD-L1, bone marrow mesenchymal technology, applied in the biological field, can solve the problems of prolonging the survival time of the graft, unable to maintain the long-term survival of the graft, etc., to prolong the survival time of the limb, delay the transplant rejection, and has a broad application prospect. Effect

Inactive Publication Date: 2012-11-07
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application of BMSCs alone cannot maintain the long-term survival of the graft, and when it is applied to allogeneic composite tissue transplantation with stronger immunogenicity, it does not significantly prolong the survival time of the graft

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PD-L1 gene modified bone marrow mesenchymal stem cells in graft rejection
  • Application of PD-L1 gene modified bone marrow mesenchymal stem cells in graft rejection
  • Application of PD-L1 gene modified bone marrow mesenchymal stem cells in graft rejection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1: Isolation, culture and identification of bone marrow mesenchymal stem cells

[0055] (1) BMSCs culture in vitro

[0056] 1.1) 4-6 weeks of healthy lewis rats were put to death with 1% pentobarbital sodium anesthesia and soaked in 75% alcohol for 10 minutes. Take out the bilateral femur, tibia and humerus from the ultra-clean workbench, remove the attached muscles and periosteum and other tissues, and soak again with 1% nitrofural solution for 5 minutes.

[0057] 1.2) After rinsing twice with PBS solution, cut off both ends of the bone to expose the bone marrow cavity, draw the pre-cooled PBS from the bone end along the long axis, and rinse the bone marrow cavity repeatedly in the petri dish to collect the bone marrow. .

[0058] 1.3) The obtained bone marrow suspension was gently pipetted repeatedly with an elbow pipette to disperse it into a cell suspension, and a 200-mesh filter was used to remove the sediment to obtain a single cell suspension. Transfer the obta...

Embodiment 2

[0064] Example 2: In vitro gene transfection of bone marrow mesenchymal stem cells and phenotype identification after transfection.

[0065] (1) Obtaining the PD-L1 gene fragment. Take 100 mg of the muscle tissue of the lower limbs of Noway-Brown rats, and use RNA-Trizol to extract RNA. Synthesized in 500ng of mRNA by Takara reverse transcription kit. Obtain rat total cDNA. The rat PD-L1 gene sequence in GeneBank is NM001191954.1, and the electrophoresis results are as follows Figure 2A As shown, this figure is the result of gel electrophoresis of rat PD-L1 gene.

[0066] (2) Construction of the lentiviral expression vector pLVpuro / EF1α-PD-L1-IRES-GFP

[0067] The four-vector system of Gateway technology was used to construct the lentiviral expression vector pLVpuro / EF1α-PD-L1-IRES-GFP. For primers containing att sites, add attB1, attB2, attB2r, and attB3 to the 5'ends of the upstream and downstream primers, respectively. Construction and identification of pLVpuro / EF1α-PD-L1-IRE...

Embodiment 3

[0074] Example 3: PD-L1 transfection of bone marrow mesenchymal stem cells induces immune tolerance

[0075] (1) In vitro experiment PD-L1 transfected BMSCs inhibited the activation and proliferation of T lymphocytes in vitro anesthetized LEWIS and BN (Norway-Brown) rats, took out the spleen, made a single cell suspension, and used RPMI1640 containing 10% FBS The cell concentration of the medium was adjusted to 5×106 / ml, and BN rat spleen cells were used as reaction cells for use. The spleen cells of LEWIS rats treated with PHA to proliferate were used as stimuli to stimulate the proliferation of BN rat T cells in vitro. Take BMSCs and PD-L1-MSCs as intervention measures to detect their inhibitory effects on lymphocyte proliferation. The results suggest that PD-L1-MSCs can significantly inhibit the proliferation of lymphocytes caused by PHA stimulation in vitro.

[0076] (2) In vivo experiment PD-L1 transfected BMSCs inhibits the rejection of limb transplantation

[0077] A) Estab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of PD-L1 gene modified bone marrow mesenchymal stem cells in graft rejection. According to the invention, immune state can be regulated and graft rejection can be inhibited, significant guidance in clinical application of xenogeneic organ transplantation is provided, foundation for inducing peripheral immune tolerance is established, and application prospect is broad.

Description

Technical field [0001] The invention belongs to the field of biotechnology, and relates to an application of stem cells in transplant rejection, and in particular to an application of bone marrow mesenchymal stem cells modified by PD-L1 gene in transplant rejection. Background technique [0002] Allogeneic composite tissue transplantation is more and more popular in the treatment of patients with large-area burns, severe deformities, or lack of tissue because they can provide good shape and functional repair. However, the rejection of transplant recipients after transplantation is the primary obstacle to successful transplantation. Although the application of various immunosuppressive agents can prevent the transplant from being rejected by the body, the long-term application brings the risk of opportunistic infections and malignant tumors, as well as the inevitable chronic rejection that severely reduces the patient’s quality of life and hinders this A clinical application of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61P37/06C12N15/64
Inventor 王耀军胡大海郑朝朱雄翔韩军涛董茂龙王耘川胡晓龙李娜李小强
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com